Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.54 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1714269 | 0.91 | GPR119 (0.64) | GPR119CHEK2 | |
| SCHEMBL2340177 | 0.90 | GPR119 (0.71) | GPR119 | |
| SCHEMBL13734979 | 0.89 | GPR119 (0.57) | GPR119SIGMAR1CHEK2 | |
| SCHEMBL13734980 | 0.89 | GPR119 (0.57) | GPR119SIGMAR1CHEK2 | |
| SCHEMBL12834985 | 0.88 | GPR119 (0.58) | GPR119CHEK2 | |
| SCHEMBL15412759 | 0.88 | GPR119 (0.58) | GPR119CHEK2 | |
| SCHEMBL3249543 | 0.88 | MGLL (0.57) | GPR119CHEK2 | |
| SCHEMBL1769099 | 0.86 | GPR119 (0.57) | GPR119CHEK2 | |
| SCHEMBL3256200 | 0.86 | GPR119 (0.57) | GPR119CHEK2 | |
| SCHEMBL2456170 | 0.86 | GPR119 (0.57) | GPR119CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-3914704-B9 | A METHOD FOR SCREENING OF AN IN VITRO DISPLAY LIBRARY WITHIN A CELL | VIPERGEN APS (DK) | 2023-10-04 | — | — | EP | disclosed |
| EP-3914704-B1 | A METHOD FOR SCREENING OF AN IN VITRO DISPLAY LIBRARY WITHIN A CELL | VIPERGEN APS (DK) | 2023-06-07 | — | — | EP | disclosed |
| US-11634835-B2 | Method for screening of an in vitro display library within a cell | VIPERGEN APS (DK) | 2023-04-25 | — | — | US | disclosed |
| US-20220090051-A1 | A METHOD FOR SCREENING OF AN IN VITRO DISPLAY LIBRARY WITHIN A CELL | VIPERGEN APS (DK) | 2022-03-24 | — | — | US | disclosed |
| EP-3914704-A1 | A METHOD FOR SCREENING OF AN IN VITRO DISPLAY LIBRARY WITHIN A CELL | Vipergen APS (DK) | 2021-12-01 | — | — | EP | disclosed |
| WO-2020152028-A1 | A METHOD FOR SCREENING OF AN IN VITRO DISPLAY LIBRARY WITHIN A CELL | VIPERGEN APS (DK) | 2020-07-30 | — | — | WO | disclosed |
| US-8796253-B2 | Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| US-8796253-B2 | Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| US-8796253-B2 | Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| US-7645773-B2 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| WO-2008141731-A2 | INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE AG (DE) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008141731-A2 | INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE AG (DE) | 2008-11-27 | — | — | WO | disclosed |
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1467995-A4 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1467995-A2 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI Pharmaceuticals, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030229067-A1 | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003053361-A2 | PYRROLOPYRIMIDINE A2b SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-1996020928-A1 | PIPERIDINE-BASED SIGMA RECEPTOR LIGANDS | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION (AU) | 1996-07-11 | — | — | WO | disclosed |
| EP-0299533-A2 | High potency sweetening agents | THE NUTRASWEET COMPANY (a Delaware corporation) (US) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | NR0B2, NR0B1, ADORA2B | GPR119 263/4885SIGMAR1 38/4885CHEK2 3514/4885 |
| US-20030229067-A1 | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use | ADORA2B, OXER1, CNR1 | GPR119 328/4885SIGMAR1 102/4885CHEK2 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.